FDA Approves Celcuity Breast Cancer Drug Revtorpyk
The FDA has approved Celcuity's Revtorpyk for advanced breast cancer after data showed it reduced the risk of disease progression by 76 percent when used in combination therapy. The company plans to launch the drug in the third quarter to target a market of over 130,000 patients.
X24 PerspectiveRelated Assets:
X24 Perspective